 Shares of Equillium Inc. EQ, -3.98 gained 12.9 in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13 people with lupus nephritis. Equillium said 83 of the participants enrolled in the study achieved complete or partial response, and about two-thirds had a 80 reduction in urine protein creatinine ratio by week 28. 